Oncologix Tech (OTCMKTS:OCLG) and Neuronetics (OTCMKTS:STIM) Head to Head Survey – Riverton Roll

Oncologix Tech (OTCMKTS:OCLG) and Neuronetics (NASDAQ:STIM) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.

Earnings & Valuation

This table compares Oncologix Tech and Neuronetics gross revenue, earnings per share and valuation.

Oncologix Tech has higher earnings, but lower revenue than Neuronetics.

Analyst Ratings

This is a summary of current recommendations and price targets for Oncologix Tech and Neuronetics, as reported by MarketBeat.com.

Neuronetics has a consensus price target of $19.50, suggesting a potential upside of 344.19%. Given Neuronetics higher probable upside, analysts clearly believe Neuronetics is more favorable than Oncologix Tech.

Volatility & Risk

Oncologix Tech has a beta of 1.56, suggesting that its stock price is 56% more volatile than the S&P 500. Comparatively, Neuronetics has a beta of 0.68, suggesting that its stock price is 32% less volatile than the S&P 500.

Insider and Institutional Ownership

78.7% of Neuronetics shares are owned by institutional investors. 39.9% of Oncologix Tech shares are owned by insiders. Comparatively, 12.0% of Neuronetics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Oncologix Tech and Neuronetics net margins, return on equity and return on assets.

Summary

Oncologix Tech beats Neuronetics on 5 of the 9 factors compared between the two stocks.

About Oncologix Tech

Oncologix Tech, Inc., a diversified medical holding company, provides health care services in the United States. It offers personal home care services, including daily living assistance, companionship, and homemaker services, as well as Alzheimer's care, home care resource planning, and medical care coordination services. The company also manufactures, markets, and distributes medical technologies and products for skilled nursing facilities, acute and critical care facilities, assisted living facilities, hospitals and medical institutions, federal agencies, home medical care industry, respiratory and therapy- physical/occupational therapy centers. In addition, it distributes and sells home medical equipment for sleep and respiratory therapies; supplies and services durable medical equipment to treat obstructive Sleep Apnea; C-PAP and BiPAP oxygen equipment, a large selection of mask interfaces; and offers personalized treatment plans, as well as monitoring and support services. The company was formerly known as BestNet Communications Corp. and changed its name to Oncologix Tech, Inc. in January 2007. Oncologix Tech, Inc. was founded in 1995 and is based in Lafayette, Louisiana.

About Neuronetics

Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with psychiatric disorders in the United States, Japan, and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrist customers. Neuronetics, Inc. was founded in 2003 and is headquartered in Malvern, Pennsylvania.

Receive News & Ratings for Oncologix Tech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncologix Tech and related companies with MarketBeat.com's FREE daily email newsletter.

View original post here:
Oncologix Tech (OTCMKTS:OCLG) and Neuronetics (OTCMKTS:STIM) Head to Head Survey - Riverton Roll